Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

ZENAPAX (daclizumab) is an immunosuppressive, humanized IgG1 monoclonal antibody produced by recombinant DNA technology that binds specifically to the alpha subunit (p55 alpha, CD25, or Tac...

Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research [1]. Shipping with dry ice.

Zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including cyclosporine and corticosteroids in patients who are not highly immunised.

2005年6月13日 · Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection. Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding.

赛尼哌 ®（达珠单抗）是一种免疫抑制，人源化的IgG1单克隆通过重组DNA技术产生的抗体特异性结合的α亚基（P55α，CD25，或TAC亚基）人高亲和力的白细胞介素-2（IL-2）受体在活化的淋巴细胞表面表达。 达克珠单抗是人（90％）和鼠（10％）抗体序列的复合物。 人序列衍生自人IgG1的恒定结构域和Eu骨髓瘤抗体的可变框架区。 鼠序列衍生自鼠抗Tac抗体的互补决定区。 由DNA序列预测的分子量为144千道尔顿。 Zenapax 25 mg / 5 mL以澄清，无菌，无色的浓缩物 …

本品含有的活性成份抗Tac单抗是一种重组并人源化的IgG1（G亚型兔免疫球蛋白）抗Tac抗体，其功能类似于白细胞介素-2 (IL-2)受体拮抗剂。 与高亲和力的IL-2受体复合物 (在激活的T细胞表面表达)... 抗Tac单抗注射液的作用 抗Tac单抗注射液副作用 抗Tac单抗注射液说明书 抗Tac单抗 本品为免疫抑制剂，适用于预防肾移植后急性排斥反应的发生，它可与包含环孢素和皮质类固醇激素的免疫抑制方案一起使用。

Zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including cyclosporine and corticosteroids in patients who are not highly immunised.

药品名称:ZENAPAX,活性成分:DACLIZUMAB,剂型:VIAL,规格:25MG/VIAL,药品注册申请号:103749,产品号:001

2003年8月31日 · Zenapax是特异性很强的抗IL-2R的单克隆抗体，有效地与IL-2竞争，从而抑制IL-2启动的T淋巴细胞增殖反应。 动物及临床试验表明，Zenapax具有选择性地免疫抑制效果，本文就Zenapax在肾移植方面的临床应用效果及其安全性作一综述。 1 作用机制